BACKGROUND Histone deacetylase (HDAC) inhibitors represent a novel class of
therapeutic agents with antitumor activity currently in clinical development. In this study, we …

Histone deacetylase (HDAC) inhibitors are a new class of anticancer agents that act by
inhibiting cancer cell proliferation and inducing apoptosis in various cancer cell lines. To …

Purpose: To assess the antitumor effects of a novel phenylbutyrate-derived histone
deacetylase (HDAC) inhibitor,(S)-HDAC-42, vis-à-vis suberoylanilide hydroxamic acid …

The anti‐epileptic drug valproic acid is also under trial as an anti‐cancer agent due to its
histone deacetylase (HDAC) inhibitory properties. However, the effects of valproic acid …

Androgen receptor (AR)-null prostate tumors have been observed in 11–24% of patients.
Histone deacetylases (HDACs) are overexpressed in prostate tumors. Therefore, HDAC …

Histone deacetylase (HDAC) inhibitors are considered novel agents for cancer
chemotherapy. We previously investigated MHY219, a new HDAC inhibitor, and its potent …

Histone deacetylase inhibitors (HDACi) are promising epigenetic cancer chemotherapeutics
rapidly approaching clinical use. In this study, we tested using in vitro and in vivo models the …

Histone deacetylase inhibitors (HDACi) represent a promising class of epigenetic agents
with anticancer properties. Here, we report that (S)-2, a novel hydroxamate-based HDACi …

Histone deacetylase inhibitors (HDACi) represent a promising new class of anticancer
agents. In the current investigation, we examined the activity of the HDACi belinostat in …

Histone deacetylase (HDAC) inhibitors are among the most promising targeted anticancer
agents and are potent inducers of growth arrest, differentiation, and/or apoptotic cell death of …